Revistă de Medicină şi Farmacie - Clujul Medical - Iuliu Haţieganu

Patologie osteoarticulară
9. Cronstein BN: Interleukin-6. A key mediator of systemic and
local symptoms in rheumatoid arthritis, Bull NYU Hosp Joint Dis,
2007, 65, Suppl 1,S 11-5.
10. Naka T, Nishimoto N, Kishimoto T: The paradigm of IL-6:
from basic science to medicine, Arthritis Res, 2002, 4, Suppl 3,
S233-242.
11. Nishimoto N, Kishimoto T: Interleukin 6: From bench to
bedside, Nat Clin Pract Rheumatol, 2006, 2, 619-626.
12. Nishimoto N, Yoshizaki K, Miyasaka N et al.: Treatment of
rheumatoid arthritis with humanized anti-interleukin-6 receptor
antibody: A multicenter, double blind, placebo-controlled trial,
Arthritis Rheum, 2004, 50, 1761-1769.
13. Smolen JS, Beaulieu A, Rubbert –Roth A et al.: Effect of
interleukin-6 receptor inhibition with tocilizumab in patients with
rheumatoid arthritis (OPTION study): a double-blind,placebo
controlled, randomized trial, Lancet 200, 371, 97-997.
14. Maini RN, Taylor PC, Szechinski J et al.: Double –blind
randomized controlled clinical trial of the interleukin-6 receptor
antagonist , tocilizumab, in European patients with rheumatoid
arthritis who had an incomplete response to methotrexate, Arthritis
Rheum, 2006, 54, 217-219.
15. Sutherland AP, Mackay F, Mackay CR: Targeting BAFF:
immunomodulation for autoimmune disease and lymphomas,
Pharmacol Ther, 2006, 112, 774-76.
16. Katselenson N, Kanswal S, Puig M, Mostowsk H, Verthelyi
D, Akkoyunlu M: Synthetic CpG oligo deoxinucleotides augment
BAFF- and APRIL-mediated immunoglobulin secretion, Eur J
Immunol, 2007, 37, 175- 1795.
17. Zhang M, Ko KH ,Lam QL et al. Expression and function of
TNF family member B cell –activating factor in the development
of autoimmune arthritis, Int Immunol, 2005, 17, 101-1092.
1. Do RK, Chen-Kiang S: Mechanism of BLyS action in cell
immunity, Cytokine Growth Factor Rev, 2002, 13, 19-25.
19. Sun J, Lin Zeno, Feng J, Li Y, Sen B: BAFF-targeting
therapy, a promising strategy for treating autoimmune diseases,
Eur J Pharmacol, 200, 597, 1-5.
20. Seyler TM, Park YW, Takemura S et al.: BLyS and APRIL
in rheumatoid arthritis, J Clin Invest, 2005, 115, 303-3092.
21. McKay J: Belimumab (BmAb), a fully human monoclonal
antibody to B-lymphocyte stimulator (BlyS), combined with
standard of care therapy reduces the signs and symptoms of
rheumatoid arthritis in a heterogenous subject population. Arthritis
Rheum, 2005, 52, Suppl 9, S 710-S 711.
22. Tak PP, Thurlings RM, Rossier et al.: Atacicept in patients
with rheumatoid arthritis:results of a multicenter, phase 1b, double
blind, placebo- controlled, dose-escalading,single- and repeated
dose study, Arthritis Rheum, 200, 5, 61-72.
23. Tsokos GC: B cells , be gone –B-cell depletion in the treatment
of rheumatoid arthritis, N Engl J Med, 2004, 350, 2546-254.
24. Lam QLK, Ko OKH, Zheng B-J, Lu L: Local BAFF gene
silencing suppresses Th 17-cell generation and ameliorates
autoimmune arthritis, Proc Nat Acad Sci USA, 200, 105, 14993-
1499.
25. Firestein GS, Zvaifler NJ: How important are T cells in chronic
rheumatoid synovitis? II .T cell –independent mechanisms from
beginning to end. Arthritis Rheum, 2002, 46, 2930.
26. Baslund B, Tvede N, Danneskiold M, Samsoe B et al.:
Targeting interleukin -15 in patients with rheumatoid arthritis :a
proof- of- concept study, Arthritis Rheum, 2005, 52, 266-292.
342
Clujul Medical 2009 Vol. LXXXII - nr. 3